KYMR: STAT6 and IRF5 programs advance in immunology, with pivotal phase II data expected by year-end

The conference highlighted advances in targeted protein degradation, with robust clinical progress for STAT6 and IRF5 programs addressing major immunology markets. Key phase II data for atopic dermatitis and asthma are expected by year-end and next year, with expansion into additional indications p…